Market Overview

UPDATE: CRT Capital Initiates Coverage on Covidien plc. at Buy, Announces $82.00 PT

Related COV
After A Blockbuster 2014, What Will 2015 Hold For Pharmaceutical M&A?
Medtronic CEO: Covidien Merger Has Accelerated Growth Strategy
Tracking The Hotchkis & Wiley Value Opportunities Fund: Q4 2014 Update (Seeking Alpha)

CRT Capital initiated coverage of Covidien (NYSE: COV) with a Buy rating and $82 price target. Shagun Chadha, analyst at CRT, believes the company “has a full pipeline and a road map to tap into five potentially $1+ billion high growth markets each.”

Shares have moved in a straight line higher since the open, now up about 1.4 percent to $71.34.

Chadha said Covidien can “consistently deliver 4-6% revenue growth lead by: a) an improvement in revenue mix towards higher-growth segments and geographies, b) new products introductions, and c) an appetite for strategic acquisitions.”

The analyst credited “solid execution” to the company's superb operational leverage, which, in addition to a non-US tax structure, provides “access to more cash to return to shareholders than its large cap medical technology peers.”

Chadha's projection “calls for 9-13% EPS growth [through 2017] with leverage from its restructuring programs.”

Latest Ratings for COV

Nov 2014JefferiesMaintainsBuy
Oct 2014Morgan StanleyDowngradesOverweightEqualweight
Jul 2014CitigroupMaintainsBuy

View More Analyst Ratings for COV
View the Latest Analyst Ratings

Posted-In: Analyst Color News Price Target Initiation Analyst Ratings


Related Articles (COV)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→